Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 52 articles: HTML format

Single Articles

August 2026
1. SUN HC, Zhu XD, Shen F, Song TQ, et al
   Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
   Lancet. 2026;408:699-710.
   PubMed     Abstract available
   
   
   
2. FORNER A
   TALENTOP study: a new era for conversion surgery in advanced hepatocellular carcinoma?
   Lancet. 2026;408:668-669.
   PubMed    
   
   
   April 2026
3. GRAUPERA I, Thiele M, Castera L, Pera G, et al
   Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.
   Lancet. 2026;407:1448-1458.
   PubMed     Abstract available
   
   
   
4. LIANG F, Zhou S, Wang Z, Fan J, et al
   Perioperative immunotherapy for resectable hepatocellular carcinoma - Authors' reply.
   Lancet. 2026;407:1334.
   PubMed    
   
   
   
5. LI Z, Tang Y
   Perioperative immunotherapy for resectable hepatocellular carcinoma.
   Lancet. 2026;407:1332.
   PubMed    
   
   
   
6. JIN W, Xue M, Luo S
   Perioperative immunotherapy for resectable hepatocellular carcinoma.
   Lancet. 2026;407:1332-1334.
   PubMed    
   
   
   March 2026
7. VON SETH E, Karlsen TH, Tanaka A, Ponsioen C, et al
   Primary sclerosing cholangitis.
   Lancet. 2026 Mar 20:S0140-6736(25)02582-6. doi: 10.1016/S0140-6736(25)02582.
   PubMed     Abstract available
   
   
   February 2026
8. VALENTI L, Periti G
   Once-monthly efimosfermin for non-cirrhotic MASH.
   Lancet. 2026 Feb 5:S0140-6736(25)02431-6. doi: 10.1016/S0140-6736(25)02431.
   PubMed    
   
   
   
9. NOUREDDIN M, Kowdley KV, Odrljin T, Bain G, et al
   Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.
   Lancet. 2026 Feb 5:S0140-6736(25)02276-7. doi: 10.1016/S0140-6736(25)02276.
   PubMed     Abstract available
   
   
   December 2025
10. SCHOENFELD JD, Haas-Kogan DA, O'Neill AF
    Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy.
    Lancet. 2025;404:2603-2604.
    PubMed    
    
    
    November 2025
11. GALLE PR, Yau T, Decaens T
    Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW - Authors' reply.
    Lancet. 2025;406:2423-2424.
    PubMed    
    
    
    
12. SHI R, Li J, Zhang L
    Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.
    Lancet. 2025;406:2422-2423.
    PubMed    
    
    
    
13. SANTHOSH A, Sreenath ND
    Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.
    Lancet. 2025;406:2421-2422.
    PubMed    
    
    
    
14. NOUREDDIN M, Harrison SA, Loomba R, Alkhouri N, et al
    Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
    Lancet. 2025 Nov 11:S0140-6736(25)02114-2. doi: 10.1016/S0140-6736(25)02114.
    PubMed     Abstract available
    
    
    October 2025
15. WANG Z, Fan J, Zhou S, Sun Y, et al
    Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Lancet. 2025 Oct 19:S0140-6736(25)01720-9. doi: 10.1016/S0140-6736(25)01720.
    PubMed     Abstract available
    
    
    
16. KASEB A, Pawlik TM
    Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma.
    Lancet. 2025 Oct 19:S0140-6736(25)02104-X. doi: 10.1016/S0140-6736(25)02104.
    PubMed    
    
    
    August 2025
17. LOOMBA R, Morgan E, Yousefi K, Li D, et al
    Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2025;406:821-831.
    PubMed     Abstract available
    
    
    
18. NOUREDDIN M, Frias JP, Neff GW, Lucas KJ, et al
    Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet. 2025;406:719-730.
    PubMed     Abstract available
    
    
    
19. KUDO M, Ren Z, Finn RS, Llovet JM, et al
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial - Authors' reply.
    Lancet. 2025;406:694.
    PubMed    
    
    
    
20. ONDER AH
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693.
    PubMed    
    
    
    
21. SHERRY AD, Dudzinski SO, Ludmir EB
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693-694.
    PubMed    
    
    
    July 2025
22. CHAN SL, Sun HC, Xu Y, Zeng H, et al
    The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
    Lancet. 2025 Jul 25:S0140-6736(25)01042-6. doi: 10.1016/S0140-6736(25)01042.
    PubMed    
    
    
    May 2025
23. VITHAYATHIL M, Sharma R
    Nivolumab plus ipilimumab in hepatocellular carcinoma.
    Lancet. 2025 May 7:S0140-6736(25)00417-9. doi: 10.1016/S0140-6736(25)00417.
    PubMed    
    
    
    
24. YAU T, Galle PR, Decaens T, Sangro B, et al
    Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
    Lancet. 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403.
    PubMed     Abstract available
    
    
    February 2025
25. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    PubMed     Abstract available
    
    
    January 2025
26. REITER FP, Geier A
    TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma.
    Lancet. 2025 Jan 8:S0140-6736(24)02680-1. doi: 10.1016/S0140-6736(24)02680.
    PubMed    
    
    
    
27. SANGRO B, Kudo M, Erinjeri JP, Qin S, et al
    Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551.
    PubMed     Abstract available
    
    
    
28. KUDO M, Ren Z, Guo Y, Han G, et al
    Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02575-3. doi: 10.1016/S0140-6736(24)02575.
    PubMed     Abstract available
    
    
    November 2024
29. ISRAELSEN M, Francque S, Tsochatzis EA, Krag A, et al
    Steatotic liver disease.
    Lancet. 2024;404:1761-1778.
    PubMed     Abstract available
    
    
    October 2024
30. PONVILAWAN B, Roth MT
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1405.
    PubMed    
    
    
    
31. QIN S
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial - Author's reply.
    Lancet. 2024;404:1405-1406.
    PubMed    
    
    
    
32. WANG JK, Liao R
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1404-1405.
    PubMed    
    
    
    
33. LI H, Yan J, Han T
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1403-1404.
    PubMed    
    
    
    September 2024
34. ADAM R, Piedvache C, Chiche L, Adam JP, et al
    Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.
    Lancet. 2024;404:1107-1118.
    PubMed     Abstract available
    
    
    
35. HEINEMANN V, Stintzing S
    Liver transplantation in metastatic colorectal cancer: a new standard of care?
    Lancet. 2024;404:1078-1079.
    PubMed    
    
    
    
36. TANAKA A, Ma X, Takahashi A, Vierling JM, et al
    Primary biliary cholangitis.
    Lancet. 2024;404:1053-1066.
    PubMed     Abstract available
    
    
    August 2024
37. MAIWALL R, Kulkarni AV, Arab JP, Piano S, et al
    Acute liver failure.
    Lancet. 2024;404:789-802.
    PubMed     Abstract available
    
    
    
38. CHOW PKH, Hack SP, Spahn JH, Yopp AC, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.
    Lancet. 2024;404:657-658.
    PubMed    
    
    
    
39. ROSE S, Ashraf MU, Premkumar M
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656-657.
    PubMed    
    
    
    
40. CHEN Z, Lan X, Du C, Xiao H, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656.
    PubMed    
    
    
    
41. DONADON M, Di Martino M, Rigamonti C
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:655-656.
    PubMed    
    
    
    
42. SHIN H, Lee JH
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:654-655.
    PubMed    
    
    
    June 2024
43. ENG C, Yoshino T, Ruiz-Garcia E, Mostafa N, et al
    Colorectal cancer.
    Lancet. 2024 Jun 20:S0140-6736(24)00360-X. doi: 10.1016/S0140-6736(24)00360.
    PubMed     Abstract available
    
    
    May 2024
44. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    PubMed    
    
    
    April 2024
45. KARLSEN TH, Rutter H, Carrieri P, Zelber-Sagi S, et al
    The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.
    Lancet. 2024;403:1522-1524.
    PubMed    
    
    
    November 2023
46. VON KODOLITSCH Y, Kubisch C, Carrel T
    AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
    Lancet. 2023;402:1626.
    PubMed    
    
    
    
47. KUEPPERS F
    AATD as a genetic risk factor for aneurysmal disease.
    Lancet. 2023;402:1625-1626.
    PubMed    
    
    
    October 2023
48. VOGEL A, Meyer T, Saborowski A
    IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
    Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.
    PubMed    
    
    
    
49. QIN S, Chen M, Cheng AL, Kaseb AO, et al
    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
    PubMed     Abstract available
    
    
    September 2023
50. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
    The price and value of therapeutic synergy in liver cancer.
    Lancet. 2023;402:1108-1110.
    PubMed    
    
    
    
51. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.
    PubMed    
    
    
    
52. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum